J.P. Morgan Day 2: What's Next For Pharma, From Alzheimer's To Omicron

Daily notebook from the virtual J.P. Morgan Healthcare Conference: Alzheimer's rivals Roche and Lilly address their attempts at a different launch for their anti-amyloid therapies than Biogen's Aduhelm. GSK is buoyed by sotrovimab's efficacy against Omicron, BioNTech looks to the future of mRNA and Sanofi, Amgen and AbbVie defend their growth strategies. 

J.P. Morgan Daily Notebook 2022 Day 2
• Source: Alamy

The US Centers for Medicare and Medicaid Services (CMS) released its national coverage determination (NCD) for anti-amyloid antibodies on 11 January, just before Eli Lilly and Company CEO David Ricks took the virtual stage at the J.P. Morgan Healthcare Conference. (Also see "Medicare Draft NCD For Alzheimer's Drugs: When 'Reasonable And Necessary' And 'Safe And Effective' No Longer Align" - Pink Sheet, 12 January, 2022.)

The decision has an immediate impact on Biogen, Inc./Eisai Co., Ltd.'s approved product Aduhelm (aducanumab), but Lilly is...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet